Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	111 women Data from 1 RCT	Adverse effects with ibuprofen with fenoprofen Absolute results not reported	OR 1.51 95% CI 0.72 to 3.18		Not significant
Systematic review	323 women 2 RCTs in this analysis	Adverse effects with naproxen with other NSAIDs Absolute results not reported	OR 1.09 95% CI 0.54 to 2.22		Not significant
RCT 3-armed trial	337 women with primary dysmenorrhoea	Adverse effects, primarily gastrointestinal 11/113 (10%) with meloxicam 7.5 mg daily 13/114 (11%) with meloxicam 15 mg daily 25/110 (23%) with mefenamic acid (500 mg three times daily)	P value reported as significant	Effect size not calculated	meloxicam
RCT Crossover design 5-armed trial	104 women with primary dysmenorrhoea	Adverse effects with ibuprofen arginate 200 mg or 400 mg with conventional ibuprofen 200 mg or 400 mg Absolute results not reported	Between group statistical assessment not reported
RCT Crossover design 3-armed trial	73 women with moderate to severe primary dysmenorrhoea	Clinical adverse effects 12% with etoricoxib 25% with naproxen sodium Absolute numbers not reported	Significance assessment not reported
RCT Crossover design 3-armed trial	73 women with moderate to severe primary dysmenorrhoea	Headache 1.5% with etoricoxib 7.5% with naproxen sodium Absolute numbers not reported	Significance assessment not reported
RCT Crossover design 3-armed trial	73 women with moderate to severe primary dysmenorrhoea	Nausea 3% with etoricoxib 3% with naproxen sodium Absolute numbers not reported	Significance assessment not reported